MENU
+Compare
HYPMY
Stock ticker: OTC
AS OF
Oct 16 closing price
Price
$3.81
Change
-$0.06 (-1.55%)
Capitalization
2.48B

HYPMY stock forecast, quote, news & analysis

Hypera SA is a specialty and generic drug manufacturing company... Show more

HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HYPMY with price predictions
Oct 16, 2025

Momentum Indicator for HYPMY turns negative, indicating new downward trend

HYPMY saw its Momentum Indicator move below the 0 level on September 30, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 114 similar instances where the indicator turned negative. In of the 114 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for HYPMY turned negative on September 30, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at .

HYPMY moved below its 50-day moving average on September 29, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HYPMY crossed bearishly below the 50-day moving average on October 02, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HYPMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HYPMY advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .

HYPMY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 261 cases where HYPMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.104) is normal, around the industry mean (17.691). P/E Ratio (17.889) is within average values for comparable stocks, (73.096). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.099). HYPMY has a moderately high Dividend Yield (0.054) as compared to the industry average of (0.030). P/S Ratio (2.002) is also within normal values, averaging (46.661).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HYPMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HYPMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Dividends

HYPMY paid dividends on January 12, 2023

Hypera SA HYPMY Stock Dividends
А dividend of $0.06 per share was paid with a record date of January 12, 2023, and an ex-dividend date of December 29, 2022. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Tilray Brands (NASDAQ:TLRY), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.93B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 52%. OVATF experienced the highest price growth at 117%, while MAJI experienced the biggest fall at -40%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -39%. For the same stocks of the Industry, the average monthly volume growth was 35% and the average quarterly volume growth was 27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 54
SMR Rating: 100
Profit Risk Rating: 90
Seasonality Score: -1 (-100 ... +100)
View a ticker or compare two or three
HYPMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
N/A
Address
Avenida Magalhaes de Castro, 4800
Phone
N/A
Employees
10301
Web
https://www.hypermarcas.com.br